High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers Trial.

[Vince]

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically unstable because of DNA repair deficiency and this is a prospective study to test that hypothesis

https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-12544&r=1